Stable transfection of the human neuroblastoma cell line SH‐SY5Y with the human 5‐hydroxytryptamine2A (5‐HT2A) or 5‐HT2C receptor cDNA produced cell lines demonstrating ligand affinities that correlated closely with those for the corresponding endogenous receptors in human frontal cortex and choroid plexus, respectively. Stimulation of the recombinant receptors by 5‐HT induced phosphoinositide hydrolysis with higher potency but lower efficacy at the 5‐HT2C receptor (pEC50 = 7.80 ± 0.06) compared with the 5‐HT2A receptor (pEC50 = 7.30 ± 0.08). Activation of the 5‐HT2A receptor caused a transient fourfold increase in intracellular Ca2+ concentration. Whole‐cell recordings of cells clamped at −50 mV demonstrated a small inward current (2 pA) in response to 10 µM 5‐HT for both receptors. There were no differences in potency or efficacy of phosphoinositide hydrolysis among four hallucinogenic [d‐lysergic acid diethylamide (LSD), 1‐(4‐iodo‐2,5‐dimethoxyphenyl)‐2‐aminopropane (DOI), 5‐methoxy‐N,N‐dimethyltryptamine, and mescaline] and three nonhallucinogenic drugs (m‐chlorophenylpiperazine, quipazine, and ergotamine). Comparison of equipotent doses producing 20% of the maximal response induced by 5‐HT revealed selective activation of the 5‐HT2A receptor by LSD and to a lesser degree by DOI, mescaline, and ergotamine. Quipazine and 5‐methoxy‐N,N‐dimethyltryptamine were relatively nonselective, whereas m‐chlorophenylpiperazine selectively activated the 5‐HT2C receptor. It is unlikely therefore that hallucinosis is mediated primarily by activity at the 5‐HT2C receptor, whereas activity at the 5‐HT2A receptor may represent an important but not unique mechanism associated with hallucinogenic drug action.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.